Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer.
Cisplatin-based chemotherapy has become an accepted standard in the adjuvant treatment of non-small-cell lung cancer (NSCLC). We present a case of acute myelogenous leukemia with an 11q23/MLL rearrangement diagnosed 1 year after the completion of 4 cycles of cisplatin and vinorelbine for resected NSCLC. To our knowledge, this is the first case of therapy-related acute myelogenous leukemia (t-AML) associated with this chemotherapy combination. The literature on t-AML with the 11q23/MLL rearrangement is reviewed.
Faller
Bryan A
BA
Department of Hematology and Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. bryan.faller@fccc.edu
Robu
Valentin G
VG
Borghaei
Hossein
H
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002880:Chromosomes, Human, Pair 11; D002945:Cisplatin / Q000008:administration & dosage; D005500:Follow-Up Studies; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000235:genetics; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics; D014178:Translocation, Genetic / Q000187:drug effects*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
C497422:KMT2A protein, human; D051788:Myeloid-Lymphoid Leukemia Protein; D014747:Vinblastine; D011495:Histone-Lysine N-Methyltransferase; D002945:Cisplatin; D000077235:Vinorelbine